Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Accumulated Expenses (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Accumulated Expenses data on record, last reported at $45.4 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 633.02% year-over-year to $45.4 million; the TTM value through Sep 2025 reached $45.4 million, up 633.02%, while the annual FY2024 figure was $39.4 million, 127.5% up from the prior year.
  • Accumulated Expenses reached $45.4 million in Q3 2025 per ZBIO's latest filing, up from $44.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $45.4 million in Q3 2025 and bottomed at $3.4 million in Q1 2025.
  • Average Accumulated Expenses over 3 years is $26.0 million, with a median of $28.3 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: soared 127.5% in 2024, then skyrocketed 633.02% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $17.3 million in 2023, then surged by 127.5% to $39.4 million in 2024, then increased by 15.21% to $45.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $45.4 million in Q3 2025, $44.5 million in Q2 2025, and $3.4 million in Q1 2025.